Navigation Links
Ontario Cancer Institute, US scientists discover compound that kills lymphoma cells
Date:4/12/2010

An international research team co-led by the Ontario Cancer Institute (OCI) has discovered a compound that kills specific lymphoma cells a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.

The research findings, published online today in Cancer Cell (DOI 0.1016/j.ccr.2009.12.050), show how the scientists used a chemical compound to block protein BCL6, the cancer-causing culprit in about half of all non-Hodgkins lymphoma cases, the fifth most common type of cancer in Canadians.

Co-principal investigator Dr. Gilbert Priv, an OCI senior scientist who specializes in analyzing the structure and function of cancer-related proteins, says: "We have identified a new avenue for drug development. It is exciting because until now, the prevailing wisdom has been that cancer proteins such as BCL6 would not respond in this way to chemical manipulation. We have proven otherwise."

The scientists began their quest using three-dimensional crystallography and computer-aided drug design to filter over one million potential compounds to about 100 that merited further research. They continued narrowing the field, down to 10 and, eventually, to the one compound that proved successful. In lab experiments, there was even better news not only did the compound kill lymphoma cells, it was also non-toxic.

Dr. Priv explains further: "If you picture cell proteins as a circuit board, we have found a way to short-circuit a defective connection without destroying the entire board. This is the potential of targeted therapy to kill specific cancer cells and leave healthy cells untouched."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1

Related biology news :

1. Cancer drug effectiveness substantially advanced
2. Disparities persist in outcomes for African-American women with advanced breast cancer
3. The immune systems guard against cancer
4. Chip checks for oral cancer
5. New discovery is a significant boost to cancer research
6. VARI study could improve treatments for prostate cancer
7. New cancer therapy may fight cardiovascular disease
8. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
9. Advances reported in quest for drugs targeting childhood cancer
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma ... its innovative TransCon technology to address significant unmet ... results for the full year ended December 31, ... year for our company as we broadened our ... leading, integrated rare disease company with an initial ...
(Date:3/22/2017)... , March 22, 2017   iSpecimen ®, ... announced that Doctors Pathology Service (DPS), a ... of the United States , has ... Delaware Health Information Network (DHIN) to make human ... The novel program, announced in 2015 as ...
Breaking Biology Technology: